Beihai Gofar Chuanshan Biological Co.Ltd(600538) (600538) announced today that from January 4, 2021 to December 23, 2021, Zhu rongjuan, the controlling shareholder of the company, and Yao Fangyuan, the person acting in concert, reduced 22.745 million shares of the company through centralized bidding and block trading, with a total reduction ratio of 4.38%.
In addition, on July 28, 2021, Beihai Gofar Chuanshan Biological Co.Ltd(600538) non-public offering of shares. Since Zhu rongjuan and Yao Fangyuan did not participate in the subscription of shares in this non-public offering, after the end of this non-public offering, the proportion of shares held by Zhu rongjuan and Yao Fangyuan in total decreased by 0.59%. To sum up, the total equity of Beihai Gofar Chuanshan Biological Co.Ltd(600538) held by Zhu rongjuan and Yao Fangyuan decreased by 5%.
Zhu rongjuan is the controlling shareholder of Beihai Gofar Chuanshan Biological Co.Ltd(600538) . After the equity change, the controlling shareholder and actual controller of Beihai Gofar Chuanshan Biological Co.Ltd(600538) have not changed.
It should be noted that on November 15, 2021, Zhu rongjuan, the controlling shareholder of Beihai Gofar Chuanshan Biological Co.Ltd(600538) , disclosed the share reduction plan. It is planned to reduce the shares of the company through centralized bidding from December 6, 2021 to March 5, 2022, which shall not exceed 1% of the total share capital of the company. By December 23, 2021, Zhu rongjuan had reduced 1945000 shares of the company (accounting for 0.37% of the total share capital of the company) through centralized bidding transaction in accordance with the above reduction plan. Up to now, the reduction plan is still in progress.
The main industries operated by Beihai Gofar Chuanshan Biological Co.Ltd(600538) include pharmaceutical manufacturing and pharmaceutical circulation industry, molecular medical imaging center and tumor radiotherapy center, tumor telemedicine technical services, molecular diagnosis and forensic technical services, etc. the main businesses are distributed in Guangxi, Guangdong, Beijing, Chongqing, Jiangsu, Shenzhen and other provinces.
It is worth mentioning that in Beihai Gofar Chuanshan Biological Co.Ltd(600538) 2020, we will complete the subscription of 100 million yuan of fund units of Huada win-win fund. Beihai Gofar Chuanshan Biological Co.Ltd(600538) the 2021 semi annual report shows that as of January 2021, Huada win-win fund has successively invested in 15 projects, including Goldman Sachs biology, Huada Zhizao, Beihai Kangcheng, Hangzhou bori, renmai biology and Tolo port. Its first investment project, Goldman Sachs biology, was acquired at the end of 2020; The IPO application of Huada Zhizao’s technology innovation board was accepted by Shanghai Stock Exchange on December 7, 2020. Beihai Kangcheng and Hangzhou bori have completed the main board IPO delivery of HKEx in June 2021. At present, the projects invested by the fund are running well.
From the perspective of operating performance, Beihai Gofar Chuanshan Biological Co.Ltd(600538) from 2012 to 2019, the deduction of non net profit has suffered losses for eight consecutive years, and the deduction of non net profit in 2020 is RMB 1.667 million. In the first three quarters of this year, Beihai Gofar Chuanshan Biological Co.Ltd(600538) realized the deduction of non net profit of 7.04 million yuan.
In the secondary market, Beihai Gofar Chuanshan Biological Co.Ltd(600538) after hitting a new low of 5.37 yuan on May 19 this year, the share price fluctuated all the way up, and hit a new high of 10.76 yuan on November 12, doubling the share price.
However, shortly afterwards, Beihai Gofar Chuanshan Biological Co.Ltd(600538) shares began to fall sharply, showing a “roller coaster” trend. Since November 24, the stock has shown a falling limit trend for three consecutive trading days, and was questioned as the reproduction of “pig killing plate”.
According to the report of the securities times at that time, in the Beihai Gofar Chuanshan Biological Co.Ltd(600538) stock bar, many netizens questioned it as a “pig killing plate”. Many investors broke the news that they bought with “Mr. Li”. Some investors also said that they had withdrawn 400000 pensions and provident fund to buy the stock.
On December 9, gf’s share price hit a phased low of 5.87 yuan, with the largest cumulative decline of 45%. As of the closing on December 24, Beihai Gofar Chuanshan Biological Co.Ltd(600538) was reported at 5.88 yuan, down 0.11 yuan or 1.84%.
(Securities Times · e company)
